Primary studies for evidence map

DetailsNotes and status
Review questionFor adults with Barrett’s oesophagus with high-grade dysplasia or intramucosal cancer, is ablative therapy effective in reducing progression to cancer and recurrence of Barrett’s oesophagus? Which is the most effective ablative therapy?
Objective(s)To determine the effectiveness of ablative therapies
Criteria for considering studiesPrimary studiesWe are not placing any restriction here on study design, but are using the results of the searches to assess the amount and level of evidence published
PopulationAdults with a diagnosis of Barrett’s oesophagus with high-grade dysplasia or intramucosal cancer
Intervention(s)Ablative therapies, specifically:
  • Risk of progression to oesophageal adenocarcinoma in those who have had ablative therapy for Barrett’s oesophagus
  • Risk of recurrence of Barrett’s oesophagus, including the development of high-grade dysplasia, after ablative therapy
  • Reported adverse effects of ablative therapy (immediate and long term)
  • Health-related quality of life
  • Resource use and costs.
How to be searchedAs per the Guidelines Manual. No additional databases are required.
Date restriction: no date restriction
Language restriction: English language
Study design: no design restriction
Review strategyTo present as a ‘map of evidence’
Using GRADE for effectiveness and adverse effects data

From: Appendix 2, Review protocol for Barrett’s oesophagus

Cover of Barrett’s Oesophagus
Barrett’s Oesophagus: Ablative Therapy for the Treatment of Barrett’s Oesophagus.
NICE Clinical Guidelines, No. 106.
Centre for Clinical Practice at NICE (UK).
Copyright © 2010, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.